Drug Profile
Research programme: thrombopoietin mimetics - STATegics
Alternative Names: STS-T4Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator STATegics
- Class Small molecules
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombocytopenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombocytopenia in USA (PO)
- 28 Mar 2012 Preclinical development is ongoing in the US
- 23 Nov 2010 Preclinical development is ongoing in the US